Lexicon Pharmaceuticals shares have gained over 50 percent year-to-date. The
company recently announced that LX1033, a treatment for irritable bowel syndrome,
has received “Fast Track” status from the FDA.
Going forward ... (see research report)
Copyright ® 2016. The Bedford Report. All Rights Reserved.